Keros Therapeutics, Inc. (KROS) — Net Income
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2025 | $87.01M | +146.4% |
| 2024 | -$187.35M | -22.5% |
| 2023 | -$152.99M | -46.2% |
| 2022 | -$104.68M | -78.2% |
| 2021 | -$58.74M | -29.5% |
| 2020 | -$45.36M | -267.7% |
| 2019 | -$12.34M | — |
| Fiscal Year | Net Income | Change YoY |
|---|---|---|
| 2025 | $87.01M | +146.4% |
| 2024 | -$187.35M | -22.5% |
| 2023 | -$152.99M | -46.2% |
| 2022 | -$104.68M | -78.2% |
| 2021 | -$58.74M | -29.5% |
| 2020 | -$45.36M | -267.7% |
| 2019 | -$12.34M | — |